LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome

Alexandra Viktoria Busley, Óscar Gutiérrez‐Gutiérrez, Elke Hammer, Fabian Koitka, Amin Mirzaiebadizi, Martin Steinegger, Constantin Pape, Linda Böhmer, Henning Schroeder, Mandy Kleinsorge, Melanie Engler, Ion Cristian Cirstea, Lothar Gremer, Dieter Willbold, Janine Altmüller, Felix Marbach, Gerd Hasenfuß, Wolfram‐Hubertus Zimmermann, Mohammad Reza Ahmadian, Bernd Wollnik, Lukas CyganekbioRxiv 2023 · DOI

TL;DR

This study uncovers a novel mechanism for recessive Noonan syndrome, where a specific mutation in the LZTR1 gene leads to protein polymerization and subsequent cardiac hypertrophy. Importantly, correcting even one copy of the mutated gene in patient-derived cells reversed the disease phenotype, offering a promising proof-of-concept for CRISPR-based gene therapies.

What Problem Does This Paper Address?

Noonan syndrome (NS) is a genetic disorder that can lead to severe early-onset hypertrophic cardiomyopathy (HCM). While mutations in the LZTR1 gene are known to increase the risk of HCM in NS patients, the precise molecular mechanisms by which these mutations cause cardiac pathology remain poorly understood. This lack of understanding limits the development of effective therapeutic strategies. This paper aims to elucidate the specific molecular and cellular consequences of a novel homozygous LZTR1 missense variant, LZTR1$^{L580P}$, to shed light on the disease mechanisms and explore potential gene-editing based therapies.

Methods

The researchers employed a multi-pronged approach:

  • Patient-derived iPSC-cardiomyocytes (iPSC-CMs): They generated induced pluripotent stem cells (iPSCs) from a patient with NS and a homozygous LZTR1$^{L580P}$ mutation. These iPSCs were then differentiated into cardiomyocytes to model the disease in a human cellular context.
  • CRISPR/Cas9 Gene Editing: To validate the role of the LZTR1$^{L580P}$ mutation, they used CRISPR/Cas9 technology to correct the mutation in patient-derived iPSCs, creating heterozygous and homozygous corrected cell lines.
  • Proteomics (LC-MS/MS): Unbiased proteomic analysis was performed on iPSC-CMs from different genetic backgrounds (WT, patient, corrected) to identify global changes in protein abundance and uncover affected pathways.
  • Western Blotting: This technique was used to confirm and quantify the protein levels of specific molecules, particularly RAS GTPases and LZTR1 itself.
  • ERK Kinase Translocation Reporter (ERK-KTR) Biosensor: This live-cell imaging tool was used to dynamically measure the activity of the RAS-MAPK signaling pathway, a key pathway implicated in NS.
  • In Silico Structural Modeling (AlphaFold-multimer): Computational tools were used to predict the structural consequences of the LZTR1$^{L580P}$ mutation on protein complex formation and interactions.
  • Engineered Heart Muscles (EHMs): To assess functional cardiac properties, iPSC-CMs were used to create 3D engineered heart tissues.
  • Immunocytochemistry: This technique was used to visualize the localization and distribution of LZTR1 proteins within cells.

Datasets

Not explicitly detailed as training/evaluation datasets in the traditional machine learning sense. The study utilizes:

  • Patient-derived iPSC lines: From a patient with NS and the LZTR1$^{L580P}$ mutation, as well as from healthy donors (WT controls).
  • CRISPR/Cas9-corrected iPSC lines: Derived from the patient's iPSCs to create isogenic controls.
  • Public Databases: Mention of gnomAD database for variant checking.

Key Insights and Ideas

  • LZTR1 Polymerization as a Novel Disease Mechanism: The most striking finding is that the homozygous LZTR1$^{L580P}$ mutation doesn't just cause a loss-of-function but leads to the formation of linear protein polymers. This polymerization disrupts the normal function of the LZTR1-cullin 3 ubiquitin ligase complex.
  • RAS GTPase Accumulation is Central: The polymerization of LZTR1 leads to the accumulation of RAS GTPases, which in turn drives the RAS-MAPK signaling hyperactivity observed in NS. This provides a clear molecular link between the LZTR1 mutation and cardiac hypertrophy.
  • Selective Degradation Pathways: The study reveals differential degradation pathways for RAS proteins. MRAS is exclusively degraded via the autophagosome by LZTR1, while RIT1 has both LZTR1-dependent and independent degradation routes, primarily through the proteasome.
  • One Functional Allele is Sufficient: Crucially, correcting just one copy of the mutated LZTR1 gene (heterozygous correction) was enough to restore normal RAS-MAPK signaling and rescue the cellular phenotype, highlighting the potential for gene therapy.
  • No Impact on Contractile Function: Despite causing hypertrophy, the LZTR1$^{L580P}$ mutation did not significantly impair the contractile function or rhythmogenesis of cardiomyocytes, suggesting that the primary issue is cellular enlargement rather than direct contractile failure.

Key Results

  • Homozygous LZTR1$^{L580P}$ causes aberrant polymerization: Ectopic expression of LZTR1$^{L580P}$ in iPSC-CMs resulted in the formation of large filaments, unlike the speckle-like pattern of WT LZTR1.
  • Accumulation of RAS GTPases: Proteomic analysis revealed significantly enhanced levels of MRAS and RIT1 in patient-derived iPSC-CMs, which were normalized upon CRISPR correction.
  • Hypertrophic Phenotype: Patient-derived iPSC-CMs displayed a significant cellular enlargement (hypertrophy), which was reversed in CRISPR-corrected cells.
  • CRISPR Correction Rescues Phenotype: Both molecular and cellular phenotypes were rescued by uni- or biallelic genetic correction of the LZTR1$^{L580P}$ variant.
  • Residual Function of LZTR1$^{L580P}$: The LZTR1$^{L580P}$ mutation preserved some residual function of the LZTR1-cullin 3 ubiquitin ligase complex, as evidenced by the continued degradation of RAS proteins, albeit at a reduced level compared to WT.

Limitations and Future Work

  • In Vitro vs. In Vivo: While iPSC-CMs and EHMs are powerful models, they are considered developmentally immature and may not fully replicate the complex disease phenotype at the organ level.
  • Technical Limitations: The study faced challenges in visualizing endogenous LZTR1 due to antibody limitations, necessitating the use of ectopic expression.
  • Future Directions:
    • Therapeutic Interventions: The study provides proof-of-concept for CRISPR-based gene therapies. Future work could focus on developing targeted compounds to prevent LZTR1 polymerization or enhance its function.
  • Domain-Specific Interactions: Further investigation into the specific domains responsible for LZTR1 homo-dimerization and polymerization is warranted.
  • Cell-Type Specificity: Exploring potential cell-type specific differences in LZTR1-RAS binding affinities could provide further insights.
  • Clinical Translation: Translating these findings into clinical applications for Noonan syndrome patients.

Summary updated

Abstract

Abstract Noonan syndrome patients harboring causative variants in LZTR1 are particularly at risk to develop severe and early-onset hypertrophic cardiomyopathy. However, the underling disease mechanisms of LZTR1 missense variants driving the cardiac pathology are poorly understood. Hence, therapeutic options for Noonan syndrome patients are limited. In this study, we investigated the mechanistic consequences of a novel homozygous causative variant LZTR1 L580P by using patient-specific and CRISPR/Cas9-corrected iPSC-cardiomyocytes. Molecular, cellular, and functional phenotyping in combination with in silico prediction of protein complexes uncovered a unique LZTR1 L580P -specific disease mechanism provoking the cardiac hypertrophy. The homozygous variant was predicted to alter the binding affinity of the dimerization domains facilitating the formation of linear LZTR1 polymer chains. The altered polymerization resulted in dysfunction of the LZTR1-cullin 3 ubiquitin ligase complexes and subsequently, in accumulation of RAS GTPases, thereby provoking global pathological changes of the proteomic landscape ultimately leading to cellular hypertrophy. Furthermore, our data showed that cardiomyocyte-specific MRAS degradation is mediated by LZTR1 via the autophagosome, whereas RIT1 degradation is mediated by both LZTR1-dependent and LZTR1-independent proteasomal pathways. Importantly, uni-or biallelic genetic correction of the LZTR1 L580P missense variant rescued the molecular and cellular disease-associated phenotype, providing proof-of-concept for CRISPR-based gene therapies.
BibTeX
@misc{busley2023lztr,
  author = {Alexandra Viktoria Busley and Óscar Gutiérrez‐Gutiérrez and Elke Hammer and Fabian Koitka and Amin Mirzaiebadizi and Martin Steinegger and Constantin Pape and Linda Böhmer and Henning Schroeder and Mandy Kleinsorge and Melanie Engler and Ion Cristian Cirstea and Lothar Gremer and Dieter Willbold and Janine Altmüller and Felix Marbach and Gerd Hasenfuß and Wolfram‐Hubertus Zimmermann and Mohammad Reza Ahmadian and Bernd Wollnik and Lukas Cyganek},
  title = {{LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome}},
  year = {2023},
  doi = {10.1101/2023.01.10.523203},
  howpublished = {bioRxiv},
}
Figure